Researchers enrolled 39 people with biomarker-confirmed mild cognitive impairment tied to Alzheimer’s disease in a phase II ...

New ADHD medications come with higher price tags but not always better results. Here’s what actually matters when choosing the right treatment.

The National Drug Control Strategy is prepared biennially by the Office of National Drug Control Policy. This document provides a strategic roadmap for the Administration to continue dismantling the ...

President Trump's new TrumpRx online platform is a key part of his plan to help lower drug costs for consumers, with some polls showing two-thirds of Americans report high health care costs as their ...

A version of this story appeared in CNN’s What Matters newsletter. To get it in your inbox, sign up for free here. The Trump administration’s undeclared war on what it calls “narco-terrorists” in ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the ...

Trump signed an executive order to lower drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. A 2024 report by the RAND Corporation found that drug ...

Attention deficit hyperactivity disorder (ADHD) is one of the most widespread neurodevelopmental conditions, impacting approximately 6 million children as well as millions of adults in the United ...

Today, the White House Office of National Drug Control Policy (ONDCP) is announcing the release of the Trump Administration’s Drug Policy Priorities, a comprehensive and coordinated blueprint to ...

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a T-cell–mediated severe cutaneous adverse reaction characterized by rash, fever, internal organ involvement, and systemic ...

Young people posting videos and photos of themselves inhaling the drug known as whippets have been going viral on social media, and although nitrous oxide—the substance the drugs are made from—is ...

Pharmacy benefit managers are driving up drug costs for millions of people, employers and the government. Credit...Photo illustration by Jens Mortensen for The New York Times Supported by By Rebecca ...